Polygenic Risk Score for Prostate Cancer Screening
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI).
Benefits of Walnut Consumption: Curbing Inflammation, Colorectal Cancer Risk
Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer, according to a recent study published by Moussa et al in Cancer Prevention Research.
Patient Support Found for AI Use as Second Reader of Mammograms
A survey study has shown cautious patient support for the use of artificial intelligence (AI) as a second reader in screening mammograms, according to results published in Radiology: Imaging Center.
Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary analysis of the trial showed that D-VMP significantly improved progression-free survival vs VMP in this setting.
Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma.
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
Sponsored by Lilly Medical Affairs
The Critical Role of Navigators in Improving Access to First-Line Precision Oncology Therapies for Advanced NSCLC
SPONSORED BY BREAST CANCER INDEX® BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making
More Top Stories
Raising Awareness of Inflammatory Breast Cancer
In late January 2013, while playing with my young son, I noticed my left breast seemed slightly larger than my right breast. Although, at the time, I had no idea this type of swelling is a hallmark of inflammatory breast cancer, a rare and aggressive disease, I immediately made an appointment with...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
Executive Orders and Cancer Care
The Association for Clinical Oncology (ASCO) is working to understand the extent and scope of several recent executive actions. ASCO recognizes the concern and confusion many are currently experiencing and understands that if there are interruptions in care and research, there can be negative...
Combination Immunotherapy Approved for Unresectable or Metastatic Hepatocellular Carcinoma
On April 11, 2025, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma. (See here for details on approval of this combination immunotherapy for colorectal...
Is This the End of Cancer Research as We Know It?
Jennifer W. Pegher, MA, MBA Emily E. Stimmel, MA Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw...
Cabozantinib Approved for Treatment of Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) recently approved the tyrosine kinase inhibitor cabozantinib (Cabometyx) for adult and pediatric patients aged 12 years and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors...
Polygenic Risk Score for Prostate Cancer Screening
In a U.K. study (BARCODE1) reported in The New England Journal of Medicine, McHugh et al found that screening for prostate cancer with a polygenic risk score was more accurate in diagnosis than screening with prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Study Details In...
